Immunotherapy of brain metastases: breaking a “dogma”
2019
Until very few years ago, the oncology community dogmatically excluded any clinical potential for immunotherapy in controlling brain metastases. Therefore, despite the significant therapeutic efficacy of monoclonal antibodies to immune check-point(s) across a wide range of tumor types, patients with brain disease were invariably excluded from clinical trials with these agents. Recent insights on the immune landscape of the central nervous system, as well as of the brain tumor microenvironment, are shedding light on the immune-biology of brain metastases.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
102
References
34
Citations
NaN
KQI